Abstract：【Objective】 To investigate the changes of plasma retinin-1(Omentin-1), serum myeloperoxidase (MPO) levels and their relationship with the severity of patients with coronary heart disease (CHD). 【Methods】 A total of 120 CHD patients (observation group) and 60 healthy volunteers were selected as control group. The levels of plasma omentin-1 and serum MPO were measured and compared between the two groups. The CHD group was stratified according to different disease types and the number of coronary lesions. 【Results】 The serum MPO level of the observation group was significantly higher than that of the control group, and the plasma omentin-1 level was significantly lower than that of the control group (P<0.05). The levels of MPO and omentin-1 in patients with acute myocardial infarction (AMI), stable angina pectoris (SAP) and unstable angina pectoris (UAP) were significantly lower than those in the control group (P<0.05). The level of serum MPO in patients with single, double and three vessel lesions increased gradually, and the difference between the groups was statistically significant (P<0.05); the level of plasma omentin-1 in patients with single, double and three vessel lesions decreased gradually, and the difference between the groups was statistically significant (P<0.05).【Conclusion】 The plasma Omentin-1 level of patients with coronary heart disease is significantly lower than that of healthy people, and the serum MPO level is significantly higher than that of healthy people. It is related to the number of coronary lesions and the severity of the disease.
吕晓燕, 马宏恩, 王鑫, 朱媛媛, 黄元哲. 冠心病患者Omentin-1、MPO水平变化及对患者病情的影响[J]. 医学临床研究, 2020, 37(4): 545-547.
LV Xiao-yan, MA Hong-en, WANG Xin, et al. Changes of Omentin-1 and MPO Levels in Patients with Coronary Heart Disease. JOURNAL OF CLINICAL RESEARCH, 2020, 37(4): 545-547.
[1] Villelabeitia-Jaureguizar K, Vicente-Campos D, Berenguel Senen A, et al. Mechanical efficiency of high versus moderate intensity aerobic exercise in coronary heart disease patients: A randomized clinical trial[J].Cardiol J,2016,34(6):90-93. [2] 朱勇,赵迎新. 脂肪因子网膜素1在冠状动脉粥样硬化性心脏病领域的相关研究进展[J].中国医药,2018,13(4):624-627. [3] 陈柏荣,危小良,彭湖,等. 髓过氧化物酶与冠状动脉慢血流的相关性[J].中国动脉硬化杂志,2015,23(2):185-187. [4] 陈秋月,肖纯. 髓过氧化物酶与动脉粥样硬化及冠心病关系的研究进展[J].山东医药,2017,57(33):104-106. [5] Qiao Y, Zhang J, Liu Y, et al. Efficacy and safety of zhenyuan capsule for coronary heart disease with abnormal glucose and lipid metabolism: study protocol for a randomized, double-blind, parallel-controlled, multicenter clinical trial[J].Evid Based Complement Alternat Med,2018,28(5):1-7. [6] 马慧,张寿涛,毛艳华,等. 老年急性冠状动脉综合征患者血浆网膜素-1、高敏C反应蛋白的表达及相关性[J].中国循环杂志,2016,31(11):1074-1078. [7] 梁思宇,肖宏凯,李向平. 冠心病患者血清髓过氧化物酶和脂氧素A4的变化[J].中国医师进修杂志,2016,39(4):354-358. [8] 李琳,李芳,肖婷,等. 冠心病患者血清活化T细胞趋化因子水平变化及与髓过氧化物酶、脂蛋白磷脂酶A2水平和全球急性冠状动脉事件注册评分的相关性[J].中国老年学杂志,2016,36(3):585-587. [9] 马春梅,吴建榕,叶道斌,等. 64排螺旋CT检测冠状动脉病变与髓过氧化物酶的相关性研究[J].中国循证心血管医学杂志,2015,7(3):339-341. [10] 台晓琳,李敖. 2型糖尿病、冠状动脉硬化性心脏病与血清脂联素、网膜素、内脏脂肪素的相关性探索[J].中国实用医药,2015,10(1):3-5.
2020, Vol. 37 
